[go: up one dir, main page]

WO1999038964A3 - Promoter regions of the mouse and human telomerase rna component genes - Google Patents

Promoter regions of the mouse and human telomerase rna component genes Download PDF

Info

Publication number
WO1999038964A3
WO1999038964A3 PCT/GB1999/000308 GB9900308W WO9938964A3 WO 1999038964 A3 WO1999038964 A3 WO 1999038964A3 GB 9900308 W GB9900308 W GB 9900308W WO 9938964 A3 WO9938964 A3 WO 9938964A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
telomerase rna
elements
cancer
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000308
Other languages
French (fr)
Other versions
WO1999038964A2 (en
Inventor
William Nicol Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to AU22912/99A priority Critical patent/AU2291299A/en
Priority to US09/601,267 priority patent/US7084267B1/en
Priority to EP99902700A priority patent/EP1049774A2/en
Priority to JP2000529424A priority patent/JP2002509699A/en
Publication of WO1999038964A2 publication Critical patent/WO1999038964A2/en
Publication of WO1999038964A3 publication Critical patent/WO1999038964A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to the identification of the genomic promoter region of the human and mouse telomerase RNA gene. Telomerase activity is necessary for the unrestricted proliferative capacity of many human cancers. It is proposed that mutation or dysregulation of the telomerase repression pathway may cause reactivation or upregulation of telomerase expression in cancer. The invention provides details of elements important for the regulation of telomerase RNA genes, including the Sp family of transcription factors. There is further provided methods for screening for elements having the ability for suppressing telomerase RNA gene promoter activity and use of such elements in the treatment of cancers. In addition, evidence is also provided for the development of new transcription based therapies for cancer and for genetic approaches to targeting therapeutic genes to cancer cells. Namely, (1) transcriptional repression and the disruption of signal transduction pathways regulating telomerase activation. (2) Tumour specific gene expression for genetic therapy via telomerase RNA gene promoters.
PCT/GB1999/000308 1998-01-29 1999-01-29 Promoter regions of the mouse and human telomerase rna component genes Ceased WO1999038964A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU22912/99A AU2291299A (en) 1998-01-29 1999-01-29 Promoter regions of the mouse and human telomerase rna component genes
US09/601,267 US7084267B1 (en) 1998-01-29 1999-01-29 Promoter regions of the mouse and human telomerase RNA component genes
EP99902700A EP1049774A2 (en) 1998-01-29 1999-01-29 Promoter regions of the mouse and human telomerase rna component genes
JP2000529424A JP2002509699A (en) 1998-01-29 1999-01-29 Mouse and human telomerase RNA component gene promoter regions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9801902.9 1998-01-29
GBGB9801902.9A GB9801902D0 (en) 1998-01-29 1998-01-29 A gene promoter

Publications (2)

Publication Number Publication Date
WO1999038964A2 WO1999038964A2 (en) 1999-08-05
WO1999038964A3 true WO1999038964A3 (en) 2000-01-20

Family

ID=10826104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000308 Ceased WO1999038964A2 (en) 1998-01-29 1999-01-29 Promoter regions of the mouse and human telomerase rna component genes

Country Status (6)

Country Link
US (1) US7084267B1 (en)
EP (1) EP1049774A2 (en)
JP (1) JP2002509699A (en)
AU (1) AU2291299A (en)
GB (1) GB9801902D0 (en)
WO (1) WO1999038964A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723987B2 (en) * 2016-09-15 2023-08-15 University Of Miami Double suicide gene vector systems for stem cells

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6777203B1 (en) 1997-11-19 2004-08-17 Geron Corporation Telomerase promoter driving expression of therapeutic gene sequences
WO1998014592A2 (en) 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
AU1474901A (en) * 1999-11-09 2001-06-06 Hybridon, Inc. Potentiation of prodrug efficacy
GB0015371D0 (en) * 2000-06-23 2000-08-16 Novartis Res Found Tumour-cell specific gene expression and its use in cancer therapy
JP4582896B2 (en) * 2000-11-22 2010-11-17 大塚製薬株式会社 K1 gene
RU2007137122A (en) 2005-03-09 2009-04-20 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем (Us) NEW hTMC PROMOTOR AND VECTORS FOR TUMOR-SELECTIVE AND HIGH-EFFECTIVE EXPRESSION OF THERAPEUTIC ANTI-CANCER GENES
US20070161031A1 (en) * 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20080220983A1 (en) * 2007-03-08 2008-09-11 Switchgear Genomics A California Corporation Functional arrays for high throughput characterization of regulatory elements in untranslated regions of genes
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
JP2022548044A (en) * 2019-09-13 2022-11-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Methods and compositions for cell and tissue rejuvenation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006486A1 (en) * 1993-09-03 1995-03-09 Government Of The United States Of America, Secretary Department Of Health And Human Services Treatment of human tumors by genetic transformation of human tumor cells
WO1996001835A1 (en) * 1994-07-07 1996-01-25 Geron Corporation Mammalian telomerase
WO1996001614A2 (en) * 1994-07-07 1996-01-25 Cold Spring Harbor Laboratory Rna component of telomerase
WO1998011207A2 (en) * 1996-09-16 1998-03-19 Geron Corporation Assays for regulators of mammalian telomerase expression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583016A (en) * 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006486A1 (en) * 1993-09-03 1995-03-09 Government Of The United States Of America, Secretary Department Of Health And Human Services Treatment of human tumors by genetic transformation of human tumor cells
WO1996001835A1 (en) * 1994-07-07 1996-01-25 Geron Corporation Mammalian telomerase
WO1996001614A2 (en) * 1994-07-07 1996-01-25 Cold Spring Harbor Laboratory Rna component of telomerase
WO1998011207A2 (en) * 1996-09-16 1998-03-19 Geron Corporation Assays for regulators of mammalian telomerase expression

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
FENG J ET AL: "THE RNA COMPONENT OF HUMAN TELOMERASE", SCIENCE, vol. 269, no. 5228, 1 September 1995 (1995-09-01), pages 1236 - 1241, XP000645335, ISSN: 0036-8075 *
GREIDER C W: "TELOMERE LENGTH REGULATION", ANNUAL REVIEW OF BIOCHEMISTRY, vol. 65, 1996, pages 337 - 365, XP002056801 *
HARLEY, C. & SHERWOOD, S.: "Telomerase, checkpoints and cancer", CANCER SURVEYS, vol. 29, 1997, pages 263 - 284, XP002117440 *
HART L R: "TISSUE- SPECIFIC PROMOTERS IN TARGETING SYSTEMICALLY DELIVERED GENE-THERAPY", SEMINARS IN ONCOLOGY, (FEB 1996) VOL. 23, NO. 1, PP. 154-158., XP002117439 *
HINKLEY, C. ET AL.: "The mouse telomerase RNA 5'-end lies just upstream of the telomerase template sequence", NUCLEIC ACIDS RESEARCH., vol. 26, 15 January 1998 (1998-01-15), OXFORD UNIVERSITY PRESS, SURREY., GB, pages 532 - 536, XP002106807, ISSN: 0305-1048 *
LANDBERG, G. ET AL.: "Telomerase activity is associated with cell cycle deregulation in human breast cancer", CANCER RESEARCH., vol. 57, 1 February 1997 (1997-02-01), pages 549 - 554, XP002117438, ISSN: 0008-5472 *
PALMITER R D ET AL: "CELL LINEAGE ABLATION IN TRANSGENIC MICE BY CELL-SPECIFIC EXPRESSION OF A TOXIN GENE", CELL, vol. 50, 31 July 1987 (1987-07-31), pages 435 - 443, XP002055685, ISSN: 0092-8674 *
PARKINSON E K ET AL: "The genetic basis of human keratinocyte immortalisation in squamous cell carcinoma development: the role of telomerase reactivation.", EUROPEAN JOURNAL OF CANCER, (1997 APR) 33 (5) 727-34, XP002117437 *
RING, C. ET AL.: "Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter", GENE THERAPY., vol. 3, 1996, pages 1094 - 1103, XP002117436, ISSN: 0969-7128 *
ZHAO, J.-Q. ET AL.: "Cloning and characterization of human and mouse telomerase RNA gene promoter sequences.", ONCOGENE, vol. 16, 1998, pages 1345 - 1350, XP002106808, ISSN: 0950-9232 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11723987B2 (en) * 2016-09-15 2023-08-15 University Of Miami Double suicide gene vector systems for stem cells

Also Published As

Publication number Publication date
WO1999038964A2 (en) 1999-08-05
US7084267B1 (en) 2006-08-01
GB9801902D0 (en) 1998-03-25
AU2291299A (en) 1999-08-16
EP1049774A2 (en) 2000-11-08
JP2002509699A (en) 2002-04-02

Similar Documents

Publication Publication Date Title
WO1999038964A3 (en) Promoter regions of the mouse and human telomerase rna component genes
EP0961833A4 (en) HUMAN PLASMA HYALURONIDASE
WO2004054512A3 (en) Therapeutic retroviral vectors for gene therapy
DK0998568T3 (en) Mutant with uracil phosphoribosyl transferase activity
HUT72987A (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
WO2002102997A3 (en) Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same
AU7585498A (en) Inhibition of p38 kinase activity by aryl ureas
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
MX9708854A (en) Gene therapy for effector cell regulation.
AU3663699A (en) Materials and methods for gene therapy
EP0848063A3 (en) Nucleic acid constructs containing hybrid promotors for use in gene therapy
Nieder et al. Relation between local result and total dose of radiotherapy for brain metastases
ATE403714T1 (en) TUMOR NECROSIS FACTOR RECEPTOR SEPARATING ENZYME, PREPARATIONS AND USES THEREOF
DE69635349D1 (en) NUCLEOTIDE SEQUENCES, PROTEINS, MEDICAMENTS AND DIAGNOSIS AGENTS FOR THE USE OF CANCER TREATMENT
CA2478616A1 (en) Use of adenoviruses mutated in the va genes for cancer treatment
WO2003027237A3 (en) Method of modulating or examining ku70 levels in cells
WO2002004610A3 (en) Regulation of human dipeptidyl-peptidase iv-like enzyme
PL349489A1 (en) Adenovirus-mediated gene therapy
WO2002008392A3 (en) Regulation of human matriptase-like serine protease
AU6296398A (en) Gene therapeutic treatment of blood vessel associated disorders
Piliero Patients reflect upon their affect-focused, experiential psychotherapy: A retrospective study
WO2002064172A3 (en) Fhit gene therapy prevents tumor development in fhit-deficient mice
WO1998029138A3 (en) Compositions and methods for tumour therapy
WO2001005353A3 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999902700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09601267

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999902700

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642